quinoxalines has been researched along with 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Booij, J; Crunelle, CL; de Bruin, K; Miller, ML; van den Brink, W | 1 |
| Beekman, FJ; Booij, J; Crunelle, CL; de Bruin, K; de Wit, TC; Ramakers, RM; van den Brink, W; van der Have, F | 1 |
2 other study(ies) available for quinoxalines and 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
| Article | Year |
|---|---|
Varenicline increases striatal dopamine D(2/3) receptor binding in rats.
Topics: Animals; Benzamides; Benzazepines; Binding Sites; Cerebellum; Corpus Striatum; Male; Nicotinic Agonists; Pyrrolidines; Quinoxalines; Radiopharmaceuticals; Random Allocation; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Varenicline | 2009 |
Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats.
Topics: Animals; Benzamides; Benzazepines; Male; Neostriatum; Nicotinic Agonists; Protein Binding; Pyrrolidines; Quinoxalines; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Tomography, Emission-Computed, Single-Photon; Varenicline | 2012 |